Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Novel Thymic Immunomodulatory Pentapeptide (TIP-5) Exhibits Anticancer Activity by Targeting the Grb2-Mediated MAPK Pathway in Breast Cancer.

Created on 03 Nov 2026

Authors

Muhammad Ijaz, Muhammad Shahbaz, Muhammad Inam, Fouzia Latif, Muhammad Hayat, Hizar Subthain

Published in

Current protein & peptide science. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Breast cancer is the most frequently diagnosed cancer and remains one of the primary causes of cancer-related deaths among women across the globe. Grb2 plays a key role in oncogenic signaling and is frequently overexpressed in breast cancer, making it a promising therapeutic target.
In this study, the anticancer potential of a novel thymic immunomodulatory pentapeptide (TIP-5) in breast cancer models was evaluated.
In vitro analyses demonstrated that TIP-5 markedly suppressed the proliferation of Grb2- overexpressing MCF-7 breast cancer cells in a dose- and time-dependent manner, while exerting minimal effects on Grb2-downregulated MCF10A normal breast epithelial cells. A time-dependent reduction in IC₅₀ values, accompanied by an increasing selectivity index, indicated enhanced preferential cytotoxicity toward cancer cells. In vivo experiments further confirmed the antitumor efficacy of TIP-5, with a 54% reduction in tumor growth at a dose of 25 mg/kg and no observable toxicity in major organs.
Mechanistic investigations revealed that TIP-5 markedly downregulated ERK expression, suggesting inhibition of the Grb2-mediated ERK/MAPK signaling pathway.
Collectively, these findings suggest that TIP-5 is a potent and selective anticancer agent with promising therapeutic potential for breast cancer treatment.

PMID:
42973339
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement